Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
The present invention provides crystalline forms of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione, and methods of making and using the same.
1. A crystalline anhydrate form of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I):
characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks at 16.7, 17.0, 17.3, 17.7, 19.0, 19.6, or 23.6° 2θ±0.2° 2θ, Form B.
2. The crystalline form of claim 1 , characterized by an XRPD pattern comprising four or more peaks at 16.7, 17.0, 17.3, 17.7, 19.0, 19.6, or 23.6° 2 θ±0.2° 2θ.
3. The crystalline form of claim 1 , characterized by an XRPD pattern comprising five or more peaks at 16.7, 17.0, 17.3, 17.7, 19.0, 19.6, or 23.6° 2 θ±0.2° 2θ.
4. The crystalline form of claim 1 , characterized by an XRPD pattern comprising peaks at 16.7, 17.0, 17.3, 17.7, 19.0, 19.6, and 23.6° 2 θ±0.2° 2θ.
5. The crystalline form of claim 1 , characterized by an XRPD pattern comprising peaks at 9.8, 10.4, 11.2, 11.8, 13.4, 13.7, 14.8, 15.8, 16.2, 16.6, 16.7, 17.0, 17.3, 17.7, 18.0, 19.0, 19.6, 20.3, 20.5, 20.8, 21.0, 21.3, 22.0, 22.3, 22.7, 23.6, 23.8, 24.4, 25.4, 25.6, 25.7, 26.3, 28.1, 28.7, and 37.2° 2 θ±0.2° 2θ.
6. The crystalline form of claim 1 , characterized by an XRPD pattern substantially as shown in FIG. 1 .
7. The crystalline form of claim 1 , characterized by a differential scanning calorimetry (DSC) thermogram having at least one endotherm with an onset of about 255° C.
8. The crystalline form of claim 1 , characterized by a DSC thermogram substantially as shown in FIG. 3 .
9. A pharmaceutical composition comprising a crystalline form of claim 1 , and one or more pharmaceutically acceptable excipients.